KBC
CTXR icon

Key Bridge Compliance’s Citius Pharmaceuticals CTXR Stock Holding History

Key Bridge Compliance’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$105K Buy
+6,165
New +$147K 0.03% 113

Other funds holding CTXR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Key Bridge Compliance's CTXR Position: Q3 2023 in Review

Key Bridge Compliance opened a new position in Citius Pharmaceuticals (CTXR) in Q3 2023: 6,165 shares worth $105K. The stake represents 0.03% of the portfolio and ranks #113 among its holdings.

74 funds tracked by Wall St. Rank hold CTXR as of Q3 2023.

  • Key Bridge Compliance held 6,165 shares of Citius Pharmaceuticals worth $105K as of Q3 2023.
  • Citius Pharmaceuticals was a new Key Bridge Compliance position in Q3 2023.
  • Citius Pharmaceuticals made up 0.03% of Key Bridge Compliance's portfolio in Q3 2023, its #113 holding.
  • 74 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2023.

Based on Key Bridge Compliance's 13F filing for Q3 2023, filed 13 Oct 2023.